MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
- LearnAboutNTM.com provides information and resources for patients and caregivers
- Site launch in support of World NTM Awareness Day, August 4
- LearnAboutNTm.com爲患者和看護人提供信息和資源。
- 支持全球貨幣世界NTm意識日的網站啓動，時間爲8月4日。
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today the launch of an educational website designed to raise awareness of nontuberculous mycobacterial (NTM) lung disease. LearnAboutNTM.com is launching today in support of World NTM Awareness Day on August 4.
康州丹伯裏和加利福尼亞州西湖村，2024年7月31日 (環球新聞通訊社)-- 曼恩凱德生物醫療公司（Nasdaq: MNKD）今日宣佈推出一款教育性網站，以提高人們對非結核分枝桿菌（NTM）肺病的認識 。LearnAboutNTm.com支持8月4日的世界NTM日正式上線。
"NTM lung disease is something many have not heard of before and that often translates to patients going undiagnosed for years," said Dr. Wassim Fares, MSc, FCCP, Senior Vice President, Therapeutic Area Head, Orphan Lung Diseases of MannKind Corporation. "MannKind is dedicated to elevating awareness of NTM, promote early detection and provide a pathway to resources with this website."
“NTm肺病是許多人之前沒有聽說過的疾病，這通常會導致患者長達多年未被診斷出來，”MannKind Corporation孤兒肺病治療領域負責人、高級副總裁Wassim Fares博士MSc,FCCP表示，“曼恩凱德致力於提高人們對NTm肺病的認識，促進早期發現，並通過該網站提供資源的途徑。”
"It's inspiring that more companies like MannKind are using their voice to amplify awareness of NTM and provide an educational tool for patients living with the disease," said Amy Leitman, JD, president of NTM Info & Research, a nonprofit advocacy group for patients with pulmonary nontuberculous mycobacterial disease. "Raising awareness helps people know the signs and for patients to access resources and ultimately timely diagnoses with physicians for optimum treatment."
"曼恩凱德等更多公司正在積極提高NTm意識併爲患有該疾病的患者提供教育工具，這令人鼓舞，" NTm 信息和研究總裁Amy Leitman表示，“提高意識有助於人們了解NTm肺病的跡象，患者能夠獲取資源，並最終獲得及時的診斷和最佳治療。”
Pulmonary NTM infection is a rare disease with a global health impact due to its rising prevalence worldwide and association with shortened life span, high morbidity, and significant impact on patients' quality of life. NTM is a group of bacteria naturally found in our environment, including water and soil, that can lead to cough, fatigue, a reduction in lung function, and poor quality of life among other debilitating symptoms. While most people are exposed to NTM daily, the organisms generally do no harm. Individuals with underlying conditions such as COPD, asthma, and bronchiectasis are at increased risk of NTM getting established in the lungs creating an infection and progressive worsening of lung function.
由於其在全球範圍內患病率的上升和與縮短壽命、高發病率和對患者生活質量的顯着影響有關，肺部NTm感染是一種罕見疾病。NTm是一組自然存在於我們的環境中，包括水和土壤中的細菌，它可能導致咳嗽、疲勞、肺功能下降、生活質量降低等其他削弱症狀。雖然大多數人每天都會接觸NTm，但通常它們對人體沒有害處。患有慢性阻塞性肺疾病、哮喘和支氣管擴張等基礎疾病的個體患病風險增加，使得NTm可以在肺部定居從而導致感染和肺功能逐漸惡化。
There are nearly 200 species of NTM, the most common is MAC (mycobacterium avium complex), which accounts for about 80% of all NTM lung disease cases in the United States. While not everyone is at risk of contracting NTM from MAC, for those who are, it can cause serious lung damage. NTM lung disease is more common in women over the age of 65. Estimated 2022 NTM disease prevalence is more than 100,000 in the U.S. and over 150,000 in Japan. Approximately 15-20% of NTM patients are refractory. The prevalence rate of NTM is increasing globally – within the U.S. alone claims-based studies suggest an annual rise of 7.5%.
共有近200種NTm，其中最常見的是MAC（分枝桿菌性肺病桿菌複合體），在美國所有NTm肺病病例中佔大約80%。儘管不是每個人都有感染MAC的NTm的風險，但對於那些有感染風險的人來說，它會導致嚴重的肺部損傷。NTm肺病在65歲以上的女性中更爲常見。據估計，2022年，NTm病的在美國超過10萬，日本超過15萬。大約15-20%的NTm患者難以治癒。NTm的患病率在全球範圍內逐年上升——在美國單獨進行的基於索賠的研究表明，每年增長7.5%。
To learn more about NTM, please visit LearnAboutNTM.com.
要了解更多關於NTm，敬請訪問LearnAboutNTm.com。
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
曼恩凱德生物醫療公司（Nasdaq：MNKD）專注於爲那些患有內分泌和孤兒肺病的患者開發和商業化創新吸入治療產品和設備。
我們致力於利用我們的配方能力和設備工程的技術，減輕糖尿病，非結核分枝桿菌（NTM）肺病，肺纖維化和肺動脈高壓等疾病的負擔。我們的標誌性技術——乾粉配方和吸入設備——可以快速，方便地向肺的深處輸送藥物，從而在目標疾病的治療方面產生局部或進入系統循環的作用，具體取決於治療目標。
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
我們致力於利用我們的配方能力和設備工程專業知識減輕糖尿病、非結核分枝桿菌（NTM）肺病、肺纖維化和肺動脈高壓等疾病的負擔。我們的標誌性技術——乾粉製劑和吸入設備——爲藥物快速、便捷地輸送到深層肺部提供了可能，這些藥物可以在當地發揮功效，也可以進入系統循環，具體取決於治療指示。
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
在曼恩凱德生物醫療的全國性合作團隊的熱情協作下，我們的使命是讓人們掌控自己的健康和自由生活。
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
請訪問mannkindcorp.com獲取更多信息，並在LinkedIn、Facebook、X或Instagram上關注我們。
MANNKIND is a registered trademark of MannKind Corporation.
曼恩凱德生物醫療是曼恩凱德的已註冊商標。
MannKind Contacts:
Corporate Communications
Christie Iacangelo
(818) 292-3500
Email: media@mnkd.com
Investor Relations
(818) 661-5000
Email: ir@mnkd.com
曼恩凱德生物醫療聯繫人：
企業通訊
電子郵件：media@mnkd.com
（818）292-3500
電子郵件：ir@mnkd.com
投資者關係
(818) 661-5000
電子郵件：ir@mnkd.com
Source: MannKind
來源：曼恩凱德生物醫療